It also reduced the risk of kidney failure and cut the risk of death from ... kidney disease but also cardiovascular disease and on all-cause death.” Ozempic and other semaglutide injections ...

Semaglutide significantly lowered the rate of complications in individuals with diabetes and chronic kidney disease. People on semaglutide saw an 18 percent drop in their risk of cardiovascular ...

US FDA Approves Novo Nordisk's Ozempic to Cut Risk of Diabetic Kidney Disease Progression (Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and ...

indicate that Ozempic cut the risk of death from kidney and cardiovascular deaths by 24%. The FDA approval of Ozempic to treat chronic kidney disease highlights a growing body of evidence showing ...

kidney failure and death from cardiovascular disease by 24% compared with placebo. Beyond that primary endpoint, Ozempic also cut the risk of major cardiovascular events by 18% and reduced the ...

Ozempic also cut the risk of cardiovascular-related deaths by 29%. "We know that, unfortunately, cardiovascular disease and chronic kidney disease just go hand in hand," Gough said. He added that ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes. The approval ...